Sarina A Piha-Paul

Trials

Studies that name Sarina A Piha-Paul as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:04 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05111561 · Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

  National Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
• Ph1/Ph2
  NCT04742959 · Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  TransThera Sciences (Nanjing), Inc. · completed · Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer · principal investigator
• Ph1
  NCT04190628 · Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  ABM Therapeutics Corporation · terminated · Advanced Solid Tumor, BRAF V600 Mutation · principal investigator
• Ph1
  NCT03654547 · Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

  TransThera Sciences (Nanjing), Inc. · completed · Advanced Solid Tumors, Triple Negative Breast Cancer · principal investigator
• Ph1
  NCT03065387 · Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

  M.D. Anderson Cancer Center · terminated · Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation · principal investigator
• Ph2
  NCT02286687 · Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

  M.D. Anderson Cancer Center · active not recruiting · Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation · principal investigator
• Ph1
  NCT01552434 · Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  M.D. Anderson Cancer Center · terminated · Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma · principal investigator
• Ph1
  NCT00880074 · FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

  M.D. Anderson Cancer Center · completed · Malignant Neoplasm · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Texas EXperimental Cancer Therapeutics Network - TEX CTN
  UM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026
  Named on NCT05111561